Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific: Bioarctic, Biocon, Innovent, Mesoblast, Simcere, Travere Therapeutics, Verrica.
Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications: Akeso, Astrazeneca, Cynata Therapeutics, Everest, Hua Medicine, Inventisbio, MEsoblast Vasomune Therapeutics.
Although it does not generally infect humans, a single mutation of the H5N1 virus in the highly pathogenic avian and bovine clade 2.3.4.4b could overcome this barrier and possibly trigger a pandemic.
Biopharma happenings in Asia-Pacific including deals and partnerships, grants, preclinical data and other news in brief: Atom Therapeutics, China Medical Systems, Congruence, Dewpoint, GSK, Keros, Martin, Mitsubishi Tanabe, Ono Pharmaceutical, Nkgen, Nkmax, Northstar Medical, Peptidream, Takeda, Zhifei.
Our immune cells are not just “defenders” against deadly viruses and pathogens but also a great balancer for tissue homeostasis. For neurological disorders, understanding the neuro-immune axis could be key to treating previously untreatable conditions such as autism spectrum disorder, according to Jun R. Huh, professor of immunology at Harvard Medical School.
During a busy day of dealmaking, Cour Pharmaceutical Development Co. Inc. entered a pact with Roche Holding AG’s Genentech unit to advance tolerogenic nanoparticle treatments for an autoimmune disease indication, garnering up to $940 million in up-front and milestone payments. Cour’s partnership with Genentech is its biggest to date, and the largest deal announced by a biopharma company on Dec. 3. A total of seven deals amounted to a combined single-day deal value of $3.67 billion.
South Korean billionaire and chairman of Celltrion Group Jungjin Seo is returning Celltrion Inc. to its contract manufacturing organization (CMO) roots, as it relies on biosimilar sales to anchor the company in a fiercely competitive novel drug R&D arena.
After raising AU$40 million (US$25.9 million) earlier this year to advance lead candidate VP-001 for treating retinitis pigmentosa type 11, PYC Therapeutics is now advancing PYC-003 to the clinic for polycystic kidney disease.
RSS
